AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. logo
ACRX

AcelRx Pharmaceuticals, Inc. (ACRX)

$2.39--

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$2.25
Day's Range
$2.4
$1.76
52-Week Range
$13.7
1 month return9.47%
3 month return58.36%
1 year return266.68%
5 year return67.13%

Company Information

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.
OrganizationAcelRx Pharmaceuticals, Inc.
Employees20
CEOMr. Vincent J. Angotti
IndustryHealth Technology

Analyst Recommendation

based on 2 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 2 Wall street analysts offering stock ratings for AcelRx Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 3363.2%

Current

$2.31

Target

$80.0

Recommendation Trend

Based on 2 analyst

Current1M Ago3M Ago
Buy
2
6
6
Hold
0
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
17.7M
Book Value
$3.68
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
6.7
PE Ratio
0.36
PEG Ratio
0.0
Wall Street Target Price
80.0

Valuation

Trailing PE0.36
Forward PE1.06
Price/Book (mrq)
0.65
Enterprise Value
14.6M
Enterprise Value/Revenue
9.59
Enterprise Value/Ebitda
0.29

Technicals

Beta
0.28
50 Day MA
3.5
200 Day MA
5.03

Institutional Holdings

Rock Springs Capital Management LP

4.25%

Vanguard Group Inc

2.51%

Geode Capital Management, LLC

0.72%

Values First Advisors Inc

0.51%

State Street Corporation

0.3%

Bridgeway Capital Management, LLC

0.2%

Discover more

Frequently Asked Questions

What is AcelRx Pharmaceuticals, Inc. share price today?

Can Indians buy AcelRx Pharmaceuticals, Inc. shares?

How can I buy AcelRx Pharmaceuticals, Inc. shares from India?

Can Fractional shares of AcelRx Pharmaceuticals, Inc. be purchased?

What are the documents required to start investing in AcelRx Pharmaceuticals, Inc. stocks?

What are today’s High and Low prices of AcelRx Pharmaceuticals, Inc.?

What are today’s traded volumes of AcelRx Pharmaceuticals, Inc.?

What is today’s market capitalisation of AcelRx Pharmaceuticals, Inc.?

What is the 52 Week High and Low Range of AcelRx Pharmaceuticals, Inc.?

How much percentage AcelRx Pharmaceuticals, Inc. is down from its 52 Week High?

How much percentage AcelRx Pharmaceuticals, Inc. is up from its 52 Week low?

What are the historical returns of AcelRx Pharmaceuticals, Inc.?

Who is the Chief Executive Officer (CEO) of AcelRx Pharmaceuticals, Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*